Korean J Intern Med.  2006 Dec;21(4):252-255. 10.3904/kjim.2006.21.4.252.

Capecitabine and Oxaliplatin (XELOX) for the Treatment of Patients with Metastatic Gastric Cancer and Severe Liver Dysfunction

• Hwang SJ
• Park JW
• Lee SD
• Kim GJ
• Sin CH
• Nam SH
• Kim BS

• KMID: 759861
• DOI: http://doi.org/10.3904/kjim.2006.21.4.252

Abstract

Gastric cancer patients with severe liver dysfunction secondary to hepatic metastases have limited treatment options. Most cytotoxic drugs have a narrow therapeutic index. Although both capecitabine and oxaliplatin have been well tolerated as single agents for patients with severe hepatic dysfunction, the combination of these drugs has not been investigated. We report here on a case of successful treatment of a patient suffering with severe liver dysfunction and metastatic gastric cancer; the patient was treated with a combination of capecitabine and oxaliplatin (XELOX). The initial bilirubin level of the patient was 10.9 mg/dL. After two cycles of treatment, his bilirubin level decreased to 2.1 mg/dL. He has experienced an excellent radiological response and he has received six cycles of XELOX chemotherapy. XELOX chemotherapy is feasible and it can be associated with positive outcomes for the patients suffering with metastatic gastric cancer and severe liver dysfunction.

Keyword

Gastric Cancer; Liver Failure; Capecitabine; Oxaliplatin

MeSH Terms

Stomach Neoplasms/complications/*pathology/surgery
Prodrugs
Organoplatinum Compounds/*therapeutic use
Middle Aged
Male
Liver Neoplasms/complications/*drug therapy/secondary
Liver Function Tests
Liver Failure/diagnosis/drug therapy/*etiology
Humans
Gastrectomy
Follow-Up Studies
Fluorouracil/*analogs & derivatives/therapeutic use
Drug Therapy, Combination
Deoxycytidine/*analogs & derivatives/therapeutic use
Antineoplastic Agents/*therapeutic use
Adenocarcinoma/complications/secondary/*therapy